Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts

Eric Ouattara, Christine Danel, Raoul Moh, Delphine Gabillard, Gilles Peytavin, Romuald Konan, Jérome Le Carrou, Franck Bohoussou, Serge P Eholie, Xavier Anglaret, Eric Ouattara, Christine Danel, Raoul Moh, Delphine Gabillard, Gilles Peytavin, Romuald Konan, Jérome Le Carrou, Franck Bohoussou, Serge P Eholie, Xavier Anglaret

Abstract

Introduction: Tenofovir (TDF) with emtricitabine (FTC) and zidovudine (ZDV) is a recognized alternate first-line antiretroviral (ART) regimen for patients who cannot start treatment with non-nucleoside reverse transcriptase inhibitors (NNRTIs). Clinical studies comparing TDF+FTC+ZDV to other regimens are lacking.

Methods: Participants in a trial of early ART in Côte d'Ivoire (Temprano ANRS 12136) started treatment with TDF/FTC plus either efavirenz (EFV) or ZDV (HIV-1+2 dually infected patients and women refusing contraception or previously treated with nevirapine). We compared rates of upper digestive serious adverse events (sAEs) between TDF/FTC+EFV and TDF/FTC+ZDV patients during the first six months of treatment. sAEs were defined as either grade 3-4 AEs or persistent grade 1-2 AEs leading to drug discontinuation.

Results: A total of 197 patients (76% women, median CD4 count 395/mm(3)) started therapy with TDF/FTC, 126 with EFV and 71 with ZDV. During the first six months of ART, 94 patients had digestive AEs (nausea/vomiting) of any grade (EFV 36/126, 29%; ZDV 58/71, 82%, p<0.0001), including 20 sAEs (EFV 3/126, 5%; ZDV 17/71, 24%, p<0.0001). In-patients on TDF/FTC+ZDV with digestive AEs, the median time to the first symptom was two days (IQR: 1-4). Plasma ZDV (Cmax) distributions and pill ZDV dosages were normal. Patients with digestive AEs had higher haemoglobin levels and tended to have higher body mass indices and more frequent past histories of cotrimoxazole (CTX) prophylaxis.

Conclusions: We observed an unexpectedly high rate of digestive sAEs in West African adults, mostly women, who started a 3-nuc ART with TDF/FTC+ZDV in Côte d'Ivoire. These adults were participating in a trial of early ART and had much higher CD4 counts than those who currently routinely start ART in sub-Saharan Africa. They all received CTX concomitantly with ZDV. We suggest that further early prescriptions of TDF+XTC+ZDV should be carefully monitored and that whenever possible, the rate of early upper digestive adverse events should be compared to that occurring in-patients taking other drug regimens.

Clinical trial number: NCT00495651.

Keywords: 3 nucleoside reverse transcriptase inhibitors; HIV infection; adults; antiretroviral treatment; early treatment; side effects; sub-Saharan Africa; tolerance.

Figures

Figure 1
Figure 1
Early drug discontinuation and viral load suppression at six months in patients who started ART with TDF-FTC-EFV or TDF-FTC-ZDV. LTFU: lost-to-follow-up; M6: Month-6.

References

    1. Toure S, Kouadio B, Seyler C, Traore M, Dakoury-Dogbo N, Duvignac J, et al. Rapid scaling-up of antiretroviral therapy in 10,000 adults in Cote d'Ivoire: 2-year outcomes and determinants. Aids. 2008;22(7):873–82.
    1. Mills EJ, Bakanda C, Birungi J, Mwesigwa R, Chan K, Ford N, et al. Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda. Aids. 2011;25(6):851–5.
    1. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. Aids. 2008;22(15):1897–1908.
    1. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. [cited 2011 May 12]. Available from: .
    1. Cuzin L, Pugliese P, Bugnon F, Delpierre C, Cua E, Billaud E, et al. Triple nucleoside reverse transcriptase inhibitor vs. non-nucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients. HIV Med. 2005;6(6):388–95.
    1. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350(18):1850–61.
    1. Masquelier B, Neau D, Boucher S, et al. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients. Antivir Ther. 2006;11(6):827–30.
    1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
    1. Munderi P, Walker AS, Kityo C, Babiker AC, Ssali F, Reid A, et al. Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts. HIV Med. 2010;11(5):334–44.
    1. Good SS, Reynolds DJ, de Miranda P. Simultaneous quantification of zidovudine and its glucuronide in serum by high-performance liquid chromatography. J Chromatogr. 1988;431(1):123–33.
    1. Langtry HD, Campoli-Richards DM. Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1989;37(4):408–50.
    1. Agence Nationale de recherche sur le Sida et les hépatites virales (ANRS) Echelle ANRS de cotation de la gravité des événements indésirables chez l'adulte. Version no6 du 9 Septembre 2003. [cited 2012 July 16]. Available from: .
    1. Clay PG. The abacavir hypersensitivity reaction: a review. Clin Ther. 2002;24(10):1502–14.
    1. Hewitt RG. Abacavir hypersensitivity reaction. Clin Infect Dis. 2002;34(8):1137–42.
    1. Yarchoan R, Mitsuya H, Myers CE, Broder S. Clinical pharmacology of 3’-azido-2’, 3’-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med. 1989;321(11):726–38.
    1. Dart Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. Aids. 2006;20(10):1391–9.
    1. Luque A, Hulse S, Wang D, Shahzad U, Tanzman E, Antenozzi S, et al. Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus. Infect Control Hosp Epidemiol. 2007;28(6):695–701.
    1. Winston A, McAllister J, Amin J, Cooper DA, Carr A. The use of a triple nucleoside–nucleotide regimen for nonoccupational HIV post-exposure prophylaxis. HIV Med. 2005;6(3):191–7.
    1. Mengelers MJ, Van Gogh ER, Kuiper HA, Pijpers A, Verheijden JH, Van Miert AS. Pharmacokinetics of sulfadimethoxine and sulfamethoxazole in combination with trimethoprim after intravenous administration to healthy and pneumonic pigs. J Vet Pharmacol Ther. 1995;18(4):243–53.
    1. Jacobson MA, Gundacker H, Hughes M, Fischl M, Volberding P. Zidovudine side effects as reported by black, Hispanic, and white/non-Hispanic patients with early HIV disease: combined analysis of two multicenter placebo-controlled trials. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;11(1):45–52.
    1. Guillemette C. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J. 2003;3(3):136–58.
    1. Hall D, Ybazeta G, Destro-Bisol G, Petzl-Erler ML, Di Rienzo A. Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenetics. 1999;9(5):591–9.
    1. Burger DM, Meenhorst PL, Koks CH, Beijnen JH. Drug interactions with zidovudine. Aids. 1993;7(4):445–60.
    1. Chatton JY, Munafo A, Chave JP, Steinhäuslin F, Roch-Ramel F, Glauser MP, et al. Trimethoprim, alone or in combination with sulphamethoxazole, decreases the renal excretion of zidovudine and its glucuronide. Br J Clin Pharmacol. 1992;34(6):551–4.
    1. Dallas S, Read SE, King S, Koren G, Bendayan R. Pharmacokinetic interaction between zidovudine and trimethoprim/sulphamethoxazole in HIV-1 infected children. Can J Infect Dis. 2000;11(5):254–8.
    1. Lee BL, Safrin S, Makrides V, Gambertoglio JG. Zidovudine, trimethoprim, and dapsone pharmacokinetic interactions in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1996;40(5):1231–6.
    1. Macleod R, Eagling VA, Sim SM, Back DJ. In vitro inhibition studies of the glucuronidation of 3′-azido-3′-deoxythymidine catalysed by human liver UDP-glucuronosyl transferase. Biochem Pharmacol. 1992;43(2):382–6.
    1. Sim SM, Back DJ, Breckenridge AM. The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes. Br J Clin Pharmacol. 1991;32(1):17–21.
    1. Moh R, Danel C, Sorho S, Sauvageot D, Anzian A, Minga A, et al. Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Cote d'Ivoire. Antivir Ther. 2005;10(5):615–24.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅